Cablevision’s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

 

Research Funding Opportunities

$8 Million SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant

Application Due Date:  November 7, 2013

The American Association for Cancer Research (AACR) is now accepting submissions of ideas for the Stand Up To Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant, which will offer up to $8 million over a three-year period.

Nobel laureate Phillip A. Sharp, Ph.D., describes convergence research as an exciting new approach that brings together the biological, computational, physical, and engineering sciences and entails not only collaboration among research groups, but also the integration of disciplinary approaches that were originally viewed as separate and distinct.

The grant provides three years of funding for research projects that must include therapeutic interventions for pancreatic cancer and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional Convergence Dream Team of experts. The project must bring together biology (e.g. genomics, epigenetics, proteomics, and/or other biological fields) and at least one additional field of research such as physics, engineering, or immunology. 

Letters of Intent for SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant projects are due by noon ET on Nov. 7, 2013, via proposalCENTRAL at https://proposalcentral.altum.com.  For general information on eligibility criteria, the application process, and other details about this Dream Team grant, visit www.AACR.org/SU2CFunding. Inquiries may be directed to the AACR Scientific Review and Grants Administration Department at 267-765-1049 or su2c@aacr.org. The SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant recipients are scheduled to be announced in spring 2014.  Read the full press release.

2013 Correlative Concepts Now Being Accepted

Application Due Date:  December 12, 2013

The Lustgarten Foundation (LF) will review Correlative Letters of intent associated with approved and funded clinical trials including those funded by CTEP.  The correlative studies proposed should be based on strong and testable hypotheses.  A clear rationale should be given for the experimental design and technical methodologies selected.  The hypotheses tested must relate to potential clinical applications such as patient monitoring for preventive or therapeutic interventions, development of new therapeutic strategies, and/or testing new biomarkers for the identification of patient subsets for specific prevention or treatment approaches.  Applications must include a statistical section describing the study design and plans for analysis of data designed to test the hypotheses.  While single center studies are acceptable, investigators are encouraged to work with muli-institutional organizations of form a consortium in order to both access sufficient numbers of patient specimens as well as ensure that assays are carried out in the most appropriate environment.

How to Apply/Deadlines

The LF has modified its application process to allow for electronic concept and full application submission. Information on how to use this site can be found in our Applicant Tutorial.

NCI Reports
 class="imageBorder"

Read recent reports from the NCI

2012 Annual Report

Learn more about our commitment in the fight against pancreatic cancer.

Join Now

Lustgarten Facebook Lustgarten Twitter Lustgarten YouTube channel

The Lustgarten Foundation
1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303

©2009 Lustgarten Foundation - 501(c)3 - CharityNavigator: 4 Stars